# Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer

> **NCT05232175** · PHASE1 · COMPLETED · sponsor: **Alteogen, Inc.** · enrollment: 290 (actual)

## Conditions studied

- Health, Subjective

## Interventions

- **DRUG:** ALT-BB4
- **DRUG:** 0.9%NaCl

## Key facts

- **NCT ID:** NCT05232175
- **Lead sponsor:** Alteogen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-18
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-08-24
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05232175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05232175, "Clinical Study of ALT-BB4 to Determine Tolerance, Safety and Pharmacokinetics in Healthy Volunteer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05232175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*